[关键词]
[摘要]
抑郁症作为一种常见的心理疾病,给患者的身心健康带来了巨大的负担,为社会卫生服务体系带来巨大挑战。临床上常用的抗抑郁化学药物主要是5-羟色胺再摄取抑制剂,疗效确切,但存在靶点单一、不良反应大、服药周期长、患者依从性差等缺点。中医药具有多靶点、多层次、多途径等特点,且不良反应小,在改善抑郁症患者症状、降低复发率等方面具有独到的优势。作为一种药用历史悠久的中药材,丹参在心脑血管疾病的防治中应用广泛,其针对抑郁症状的治疗近年来也被频繁使用,在抗抑郁领域展现出潜在治疗效果。对丹参有效成分水溶性成分(丹酚酸B、迷迭香酸、咖啡酸、丹参素钠)、脂溶性成分(丹参酮、丹参酮ⅡA、隐丹参酮)及丹参类制剂(注射用丹参多酚酸、复方丹参滴丸等)在抗抑郁药理作用及机制的研究进展进行系统总结,旨在为丹参进一步开发和临床应用提供科学依据,为抑郁症治疗提供新思路。
[Key word]
[Abstract]
As a common mental illness, depression has brought a huge burden to the physical and mental health of patients and brought great challenges to the social health service system. The commonly used antidepressant chemical drugs in clinical practice are serotonin reuptake inhibitors, which have definite therapeutic effects. However, they have disadvantages such as single target, large adverse reactions, long medication cycles, and poor patient compliance. Traditional Chinese medicine has the characteristics of multi-target, multi-level, and multi pathway, and has minimal adverse reactions. It has unique advantages in improving symptoms of depression patients and reducing recurrence rates. As a traditional Chinese medicine with a long history, Salviae Miltiorrhizae Radixet Rhizomais widely used in the prevention and treatment of cardiovascular and cerebrovascular diseases. Its treatment for depressive symptoms has also been frequently used in recent years, showing potential therapeutic effects in the field of antidepressants. In this paper, the research progress of water-soluble components (salvianolic acid B, rosmarinic acid, caffeic acid, sodium danshensu), fat-soluble components (tanshinone, tanshinone IIA, cryptotanshinone) and salvia preparations (Salvianolic Acids for Injection, Compound Danshen Dropping Pills, etc.) in antidepressant pharmacological effects were systematically summarized, aiming to provide scientific basis for the further development and clinical application of Salviae Miltiorrhizae Radix et Rhizoma, and provide new ideas for the treatment of depression.
[中图分类号]
R285.5
[基金项目]
天津市制造业高质量发展专项资金—天津天士力之骄药业有限公司技术中心创新能力建设(ZZY20232088)